Canopy Growth Corporation (CGC) Stock Dips While Market Gains: Key Facts

In the latest close session, Canopy Growth Corporation (CGC) was down 1.85% at $1.06. The stock fell short of the S&P 500, which registered a gain of 0.13% for the day. Elsewhere, the Dow gained 0.45%, while the tech-heavy Nasdaq added 0.03%. The company's stock has dropped by 1.82% in the past month, falling short of the Medical sector's gain of 1.01% and the S&P 500's gain of 5.25%.The upcoming earnings release of Canopy Growth Corporation will be of great interest to investors. The company's earnings report is expected on June 15, 2026. The company is predicted to post an EPS of -$0.06, indicating a 93.62% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $53.26 million, up 17.56% from the prior-year quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.36 per share and a revenue of $210.58 million, representing changes of +87.92% and +8.94%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Canopy Growth Corporation presently features a Zacks Rank of #3 (Hold). The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 153, this industry ranks in the bottom 38% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks